1809 related articles for article (PubMed ID: 11433224)
1. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G
J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
[TBL] [Abstract][Full Text] [Related]
2. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
[TBL] [Abstract][Full Text] [Related]
4. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
Gerbes AL; Gülberg V; Ginès P; Decaux G; Gross P; Gandjini H; Djian J;
Gastroenterology; 2003 Apr; 124(4):933-9. PubMed ID: 12671890
[TBL] [Abstract][Full Text] [Related]
5. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
[TBL] [Abstract][Full Text] [Related]
6. Evidence that chronicity of hyponatremia contributes to the high urate clearance observed in the syndrome of inappropriate antidiuretic hormone secretion.
Decaux G; Prospert F; Soupart A; Musch W
Am J Kidney Dis; 2000 Oct; 36(4):745-51. PubMed ID: 11007676
[TBL] [Abstract][Full Text] [Related]
7. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone.
Decaux G; Musch W
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1175-84. PubMed ID: 18434618
[TBL] [Abstract][Full Text] [Related]
8. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
9. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Decaux G
Semin Nephrol; 2009 May; 29(3):239-56. PubMed ID: 19523572
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
12. Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia.
Decaux G; Schlesser M; Coffernils M; Prospert F; Namias B; Brimioulle S; Soupart A
Clin Nephrol; 1994 Aug; 42(2):102-8. PubMed ID: 7955571
[TBL] [Abstract][Full Text] [Related]
13. [Hyponatremia secondary to inappropriate antidiuretic hormone secretion].
Zamboli P; De Nicola L; Minutolo R; Iodice C; Avino D; Mascia S; D'Angiò P; Calabria M; Conte G
G Ital Nefrol; 2008; 25(5):554-61. PubMed ID: 18985840
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
15. SIADH and other hyponatremic disorders: diagnosis and therapeutic problems.
Saito T
Nihon Jinzo Gakkai Shi; 1996 Oct; 38(10):429-34. PubMed ID: 8940823
[TBL] [Abstract][Full Text] [Related]
16. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
Alcázar Arroyo R
Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
[TBL] [Abstract][Full Text] [Related]
17. Normal fractional urate excretion identifies hyponatremic patients with reset osmostat.
Imbriano LJ; Ilamathi E; Ali NM; Miyawaki N; Maesaka JK
J Nephrol; 2012; 25(5):833-8. PubMed ID: 22307440
[TBL] [Abstract][Full Text] [Related]
18. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Ghali JK; Zmily HD; Farah JO; Daifallah S
IDrugs; 2010 Nov; 13(11):782-92. PubMed ID: 21046526
[TBL] [Abstract][Full Text] [Related]
19. Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance.
Decaux G; Namias B; Gulbis B; Soupart A
J Am Soc Nephrol; 1996 May; 7(5):805-10. PubMed ID: 8738818
[TBL] [Abstract][Full Text] [Related]
20. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
